QI Xiang, JIANG Song-wei, YUAN Ying-hui, XU Li, HUI Zi*, YE Xiang-yang*, XIE Tian*. Advances in antiviral research of adaptor-associated protein kinase 1 (AAK1) inhibitorsJ. Acta Pharmaceutica Sinica, 2022,57(7): 1991-2002. doi: 10.16438/j.0513-4870.2022-0155
Citation: QI Xiang, JIANG Song-wei, YUAN Ying-hui, XU Li, HUI Zi*, YE Xiang-yang*, XIE Tian*. Advances in antiviral research of adaptor-associated protein kinase 1 (AAK1) inhibitorsJ. Acta Pharmaceutica Sinica, 2022,57(7): 1991-2002. doi: 10.16438/j.0513-4870.2022-0155

Advances in antiviral research of adaptor-associated protein kinase 1 (AAK1) inhibitors

  • As one of the major sources of infection, viruses could infect all organisms including bacteria, plants, animals, and humans. Infectious diseases caused by viruses pose a great threat and damage to human health and economic activities all over the world. Adaptor-associated protein kinase 1 (AAK1) is a member of the Ark1/Prk1 family of serine/threonine kinases and a specific key kinase regulating the phosphorylation of AP-2 protein μ2 subunit T156. In the past, AAK1 has been regarded as a feasible biological target for the treatment of nerve pain. Recently, scientists have found that inhibiting AAK1 can regulate endocytosis and inhibit virus invasion into cells. Therefore, AAK1 could be the potential target of anti-virus therapy. This paper reviews the research progress of small molecule AAK1 inhibitors in the field of antiviral, analyzes the future research directions and challenges, and provides new ideas for the development of antiviral drugs targeting AAK1.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return